LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $76 Up From $67 Price Target 4/4/2018 3:56:22 PM
  • Wedbush Is Increasing Ascendis Pharma A/S (ASND) 2018 Estimate To -3.14 From -3.53 2/26/2018 1:19:52 PM
  • Wedbush Is Increasing Ascendis Pharma A/S (ASND) 4Q18 Estimate To -0.81 From -0.91 2/26/2018 1:19:30 PM
  • Wedbush Is Raising Ascendis Pharma A/S (ASND) 3Q18 Estimate To -0.79 From -0.89 2/26/2018 1:19:11 PM
  • Wedbush Is Raising Ascendis Pharma A/S (ASND) 2Q18 Estimate To -0.78 From -0.87 2/26/2018 1:18:48 PM
  • Wedbush Is Raising Ascendis Pharma A/S (ASND) 1Q18 Estimate To -0.77 From -0.86 2/26/2018 1:18:30 PM
  • Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $67 Price Target 2/26/2018 1:16:10 PM
  • Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $62 Price Target 2/6/2018 7:57:20 AM
  • Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $62 Price Target 11/29/2017 6:27:53 AM
  • Wedbush Is Lowering Ascendis Pharma A/S (ASND) 2018 Estimate To -3.53 From -2.81 11/29/2017 6:26:54 AM
  • Wedbush Is Cutting Ascendis Pharma A/S (ASND) Q4 18 Estimate To -0.91 From -0.72 11/29/2017 6:26:34 AM
  • Wedbush Is Lowering Ascendis Pharma A/S (ASND) Q3 18 Estimate To -0.89 From -0.71 11/29/2017 6:26:21 AM
  • Wedbush Is Lowering Ascendis Pharma A/S (ASND) Q2 18 Estimate To -0.87 From -0.70 11/29/2017 6:26:08 AM
  • Wedbush Is Lowering Ascendis Pharma A/S (ASND) Q1 18 Estimate To -0.86 From -0.68 11/29/2017 6:25:54 AM
  • Wedbush Is Cutting Ascendis Pharma A/S (ASND) 2017 Estimate To -3.60 From -3.05 11/29/2017 6:25:33 AM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap